PRURIGO NODULARIS
Clinical trials for PRURIGO NODULARIS explained in plain language.
Never miss a new study
Get alerted when new PRURIGO NODULARIS trials appear
Sign up with your email to follow new studies for PRURIGO NODULARIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could dupixent help kids with chronic itchy skin disease?
Disease control Recruiting nowThis study tests the drug dupilumab (Dupixent) in 18 children aged 6 months to 18 years with prurigo nodularis, a condition causing very itchy skin bumps. The main goals are to measure how the drug moves through the body and to check for side effects. Participants receive injecti…
Matched conditions: PRURIGO NODULARIS
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New Real-World study tests nemolizumab for chronic itch condition
Symptom relief Recruiting nowThis study looks at how well the drug nemolizumab works for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. Researchers will track 600 participants over 6 months in real-world clinics, measuring itch severity and skin lesi…
Matched conditions: PRURIGO NODULARIS
Sponsor: Galderma R&D • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New shot aims to stop the maddening itch of prurigo nodularis
Symptom relief Recruiting nowThis study tests an injection called SHR-1819 to see if it can safely reduce the intense itching caused by prurigo nodularis, a chronic skin condition with hard, itchy bumps. About 423 adults will receive either the drug or a placebo, and researchers will track how much their wor…
Matched conditions: PRURIGO NODULARIS
Phase: PHASE2, PHASE3 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC